HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oncogenic shock: turning an activated kinase against the tumor cell.

Abstract
Accumulating evidence indicates that mutationally activated kinases are especially good targets for anti-cancer drugs. It has been suggested that this reflects a state of "oncogene addiction" of tumor cells. We recently reported experimental studies that may provide a molecular mechanism to explain such apparent dependency. We find that oncogenic kinases produce both pro-survival and pro-apoptotic signals that decay at different rates upon oncogene inactivation. Pro-survival signals are rapidly attenuated, whereas pro-apoptotic signals are relatively longer-lived. This differential signal decay creates a temporal window during which pro-apoptotic outputs from the oncogenic kinase predominate to actively promote tumor cell death upon kinase inhibition. We refer to this mechanism as "oncogenic shock", and suggest that it has significant implications for the optimal therapeutic use of targeted kinase inhibitors.
AuthorsSreenath V Sharma, Jeffrey Settleman
JournalCell cycle (Georgetown, Tex.) (Cell Cycle) Vol. 5 Issue 24 Pg. 2878-80 (Dec 2006) ISSN: 1551-4005 [Electronic] United States
PMID17218790 (Publication Type: Journal Article)
Chemical References
  • Protein Kinases
Topics
  • Animals
  • Apoptosis
  • Mice
  • Models, Biological
  • Neoplasms (enzymology)
  • Protein Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: